365 related articles for article (PubMed ID: 25140909)
1. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects.
Spreen W; Ford SL; Chen S; Wilfret D; Margolis D; Gould E; Piscitelli S
J Acquir Immune Defic Syndr; 2014 Dec; 67(5):481-6. PubMed ID: 25140909
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
Landovitz RJ; Li S; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Zhang Y; Tolley E; Sugarman J; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Spreen WR; Cohen MS; McCauley M; Eron JJ
PLoS Med; 2018 Nov; 15(11):e1002690. PubMed ID: 30408115
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults.
Spreen W; Williams P; Margolis D; Ford SL; Crauwels H; Lou Y; Gould E; Stevens M; Piscitelli S
J Acquir Immune Defic Syndr; 2014 Dec; 67(5):487-92. PubMed ID: 25473882
[TBL] [Abstract][Full Text] [Related]
4. Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat.
Jucker BM; Alsaid H; Rambo M; Lenhard SC; Hoang B; Xie F; Groseclose MR; Castellino S; Damian V; Bowers G; Gupta M
J Control Release; 2017 Dec; 268():102-112. PubMed ID: 29042321
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.
Verloes R; Deleu S; Niemeijer N; Crauwels H; Meyvisch P; Williams P
HIV Med; 2015 Sep; 16(8):477-84. PubMed ID: 25988676
[TBL] [Abstract][Full Text] [Related]
7. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
Landovitz RJ; Li S; Eron JJ; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Eshleman SH; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Cohen MS; McCauley M; Hendrix CW
Lancet HIV; 2020 Jul; 7(7):e472-e481. PubMed ID: 32497491
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor.
Spreen W; Min S; Ford SL; Chen S; Lou Y; Bomar M; St Clair M; Piscitelli S; Fujiwara T
HIV Clin Trials; 2013; 14(5):192-203. PubMed ID: 24144896
[TBL] [Abstract][Full Text] [Related]
9. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
[TBL] [Abstract][Full Text] [Related]
10. Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis.
Shaik JS; Weld ED; Edick S; Fuchs E; Riddler S; Marzinke MA; D'Amico R; Bakshi K; Lou Y; Hendrix C; Han K; Ford SL; Margolis D; Spreen W; Patel P
Br J Clin Pharmacol; 2022 Feb; 88(4):1667-1678. PubMed ID: 34240467
[TBL] [Abstract][Full Text] [Related]
11. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.
McGowan I; Dezzutti CS; Siegel A; Engstrom J; Nikiforov A; Duffill K; Shetler C; Richardson-Harman N; Abebe K; Back D; Else L; Egan D; Khoo S; Egan JE; Stall R; Williams PE; Rehman KK; Adler A; Brand RM; Chen B; Achilles S; Cranston RD
Lancet HIV; 2016 Dec; 3(12):e569-e578. PubMed ID: 27658864
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the
Han K; Gevorkyan H; Sadik Shaik J; Crauwels H; Leemereise C; Bontempo G; Win B; Chounta V; Seal C; DeMoor R; D'Amico R; Spreen WR; Ford SL
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0078123. PubMed ID: 38038460
[TBL] [Abstract][Full Text] [Related]
13. Long-acting injectable antiretrovirals for HIV treatment and prevention.
Spreen WR; Margolis DA; Pottage JC
Curr Opin HIV AIDS; 2013 Nov; 8(6):565-71. PubMed ID: 24100877
[TBL] [Abstract][Full Text] [Related]
14. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects.
Ford SL; Lou Y; Lewis N; Kostapanos M; D'Amico R; Spreen W; Patel P
Antivir Ther; 2019; 24(4):301-308. PubMed ID: 30896438
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV.
Thoueille P; Saldanha SA; Schaller F; Choong E; Veuve F; Munting A; Cavassini M; Braun D; Günthard HF; Duran Ramirez JJ; Surial B; Furrer H; Rauch A; Ustero P; Calmy A; Stöckle M; Di Benedetto C; Bernasconi E; Schmid P; Marzolini C; Girardin FR; Buclin T; Decosterd LA; Guidi M;
Clin Pharmacol Ther; 2024 Jun; 115(6):1450-1459. PubMed ID: 38519844
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, safety and tolerability of long-acting parenteral intramuscular injection formulations of doravirine.
Yee KL; Mittal S; Fan L; Triantafyllou I; Dockendorf MF; Fackler PH; Stoch SA; Khalilieh SG; Iwamoto M
J Clin Pharm Ther; 2020 Oct; 45(5):1098-1105. PubMed ID: 32501541
[TBL] [Abstract][Full Text] [Related]
17. A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV.
Cranston RD; Dezzutti CS; Siegel A; Engstrom J; Shetler C; Richardson-Harman N; Abebe KZ; Back D; Else L; Egan D; Khoo S; Egan JE; Stall R; Williams P; Brand RM; Parikh UM; McGowan I
AIDS Res Hum Retroviruses; 2019 Sep; 35(9):794-804. PubMed ID: 31146534
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques.
McMillan J; Szlachetka A; Zhou T; Morsey B; Lamberty B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
AIDS; 2019 Mar; 33(3):585-588. PubMed ID: 30289818
[TBL] [Abstract][Full Text] [Related]
19. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.
Andrews CD; Spreen WR; Mohri H; Moss L; Ford S; Gettie A; Russell-Lodrigue K; Bohm RP; Cheng-Mayer C; Hong Z; Markowitz M; Ho DD
Science; 2014 Mar; 343(6175):1151-4. PubMed ID: 24594934
[TBL] [Abstract][Full Text] [Related]
20. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
